Efficacy and safety of topical dapsone versus topical tetracycline in mild to moderate acne vulgaris: a retrospective analysis

Yıl 2025, Cilt: 15 Sayı: 1, 1 - 5, 30.04.2025

Sabir Hasanbeyzade

Öz

Objective: In this study,we compared the efficacy and side effects of topical 7.5% dapsone and 3% tetracycline in patients with mild and moderate acne.
Methods: The study was approved by the hospital’s clinical Ethics Committee.A total of 100 subjects aged 12-40 years were enrolled in the study and each group contained 50 subjects who applied to the dermatology clinic with the complaint of acne on 01.09.22-30.11.22,were diagnosed with mild and moderate acne,and were treated with topical 7.5% dapsone or 3% tetracycline for at least 12 weeks.
Results: A statistically significant difference was found between the 2 groups in terms of acne scores and lesion numbers at the end of the treatment (p=0.006 for acne score,0.002 for open comedones and <0.001 for other types of lesions).There was also a significant difference between the 2 groups in terms of patients with an acne score of 0 or 1 after 12 weeks of treatment (p=0.007).At the end of the first month,there was a difference between the 2 groups in terms of erythema,dryness and burning/stinging side effects (respectively p=0.009, 0.009 and <0.001).
Conclusion: Our results suggest that topical 7.5% dapsone is effective in the treatment of mild to moderate acne and is safe in terms of side effects compared to topical 3% tetracycline.

Anahtar Kelimeler

topical dapsone , acne and dapsone , tetracycline and dapsone , topical tetracycline

Kaynakça

• 1. Zhou M, Yang M, Zheng Y, Dong K, Song L, He C, et al. Skin surface lipidomics revealed the correlation between lipidomic profile and grade in adolescent acne. J Cosmet Dermatol. 2020;19:3349–56.
• 2. Poli F, Auffret N, Leccia MT, Claudel J-P, Dréno B. Truncal acne, what do we know? J Eur Acad Dermatol Venereol. 2020;34:2241–6.
• 3. Dréno B, Araviiskaia E, Kerob D, Andriessen A, Anfilova M, Arenbergerova M, et al. Nonprescription acne vulgaris treatments: Their role in our treatment armamentarium-An international panel discussion. J Cosmet Dermatol. 2020;19:2201–11.
• 4. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–24.
• 5. Sago J, Hall RP. Dapsone. Dermatol Ther. 2002;15:340–51.
• 6. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001;19:79–86, viii.
• 7. Schmitdt E, Reimer S, Kruse N, Bröcker EB, Zillikens D. The IL-8 release from human keratinocytes, mediated by anti-bodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2001;124:157–62.
• 8. Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear. Skin Pharmacol. 1995;8:196–202.
• 9. Stein Gold LF, Jarratt MT, Bucko AD, Grekin SK, Berlin JM, Bukhalo M, et al. Efficacy and safety of once-daily dapsone gel, 7. 5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(5):553–61.
• 10. Eichenfield LF, Lain T, Frankel EH, Jones TM, Chang-Lin J-E, Berk DR, et al. Efficacy and safety of oncedaily dapsone gel 7. 5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J Drugs Dermatol. 2016;15(8):962–9.
• 11. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the effi cacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439.e1–10.
• 12. Faghihi G, Rakhshanpour M, Abtahi-Naeini B, Nilforoushzadeh MA. The effi cacy of 5% dapsone gel plus oral isotretinoin versus oral isotretinoin alone in acne vulgaris: A randomized double-blind study. Adv Biomed Res. 2014;3:177.
• 13. Lucky AW, Maloney MJ, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6:981–7.